^
Association details:
Biomarker:MYC rearrangement + BCL6 rearrangement
Cancer:Follicular Lymphoma
Regimen:EPOCH-R (cyclophosphamide + doxorubicin hydrochloride + etoposide IV + + Rituxan (rituximab) + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

FOLLICULAR LYMPHOMA WITH C-MYC REARRANGEMENT. PLACE OF THERAPY INTENSIFICATION.

Published date:
05/17/2018
Excerpt:
In a group of 5 pts after R-DA-EPOCH, 2 pts had complete remission (CR) (one case of FL 3A with c-MYC/BCL2-R, another case of FL 3B with solely c-MYC-R), 3 pts needed second-line treatment (R-DHAP) due to progressive disease (PD) (2 cases of FL 3B with c-MYC/BCL6-R) or partial remission (PR) (1 case of FL 3A with c-MYC/BCL2-R). The last one achieved CR after 2 R-DHAP, later auto-SCT was performed. Another pt had stable disease (SD), auto-SCT was planned.